Wockhardt Recalls Metoprolol Succinate Tablets Due to Complaint Investigation Failures
Wockhardt USA is recalling Metoprolol Succinate Extended-Release Tablets because the firm did not adequately investigate customer complaints.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II and involves a CGMP deviation regarding complaint investigation without reported illnesses or injuries, fitting the criteria for a moderate severity voluntary precautionary recall.
Plain-English summary
Wockhardt USA Inc. is recalling Metoprolol Succinate Extended-Release Tablets, USP, 25 mg. The affected products are packaged in 100-count bottles, 500-count bottles, 8,000-count pouches for repacking, and 12 x 30 tablet dispenser pack cartons. The tablets are prescription-only and were manufactured by Wockhardt Limited in Mumbai, India.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. Specifically, the firm did not adequately investigate customer complaints. The affected lots have expiration dates ranging from April 30, 2015, to June 30, 2015.
The products were distributed nationwide in the United States, including Puerto Rico. Consumers and healthcare providers should stop using the affected products and contact their healthcare provider or pharmacist for guidance on alternative treatment options.
The recalled product
- Product
- Metoprolol Succinate Extended-Release Tablets, USP, 25 mg Tablets, Packaged in A) 100 Count Bottles (NDC: 64679-0734-02), B) 500 Count Bottles (NDC: 64679-0734-03), C) 8000 Count Pouches, For Repacking Only (NDC: 64679-734-08) and D) 12 x 30 Tablet Dispenser Pack Cartons (NDC: 64
- Manufacturer
- Wockhardt Usa Inc.
- Category
- Drug — Prescription Medication
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- A) Lot #: LN11050
- Expiry: 4/30/2015
- Lot #: LN11053
- Lot #: LN11169
- Expiry: 5/31/2015
- Lot #: LN11312
- Expiry: 6/30/2015
- Lot #: LN11313
- Lot #: LN11318
- Expiry: 6/30/2015. B) Lot #: LN11030
- Lot #: LN11031
- Lot #: LN11032
- Lot #: LN11038
- Lot #: LN11042
- Expiry
- 4/30/2015
- Lot #: LN11047
- Lot #: LN11173
- Lot #: LN11289
- Lot #: LN11293
Distribution
Part of a larger recall action
This product is one of 35 recalled by Wockhardt Usa Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 35 products in this recall →Related recalls
Same manufacturer · Wockhardt Usa Inc.
See all →- LowWockhardt Recalls Enalapril Maleate Tablets Due to Impurity Failures
FDA (Drugs) · 2017-11-01
- ModerateWockhardt Recalls Lisinopril Tablets Due to Inadequate Complaint Investigations
FDA (Drugs) · 2015-08-26
- ModerateWockhardt Recalls Lisinopril Tablets Due to Inadequate Complaint Investigations
FDA (Drugs) · 2015-08-26
- ModerateWockhardt Recalls Azithromycin Tablets Due to Complaint Investigation Failures
FDA (Drugs) · 2015-07-29
- ModerateWockhardt Recalls Zolpidem Tartrate Tablets Due to Complaint Investigation Failures
FDA (Drugs) · 2015-07-29
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- SevereShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19